Shire posts better-than-expected 13 pct rise in Q4 earnings
February 11, 2016 at 07:15 AM EST
LONDON, Feb 11 (Reuters) - Shire, the London-listed drugmaker buying Baxalta International for $32 billion, reported a better-than-expected 13 percent rise in fourth-quarter earnings on Thursday, helped by strong sales of its ADHD treatment Vyvanse.
